TRUSTFULL
26.3.2024 21:20:28 CET | Business Wire | Press release
Trustfull, a leading risktech platform utilizing silent checks on phone, email, IP address, and device intelligence to combat fraud across onboarding, authentication, and payments, announces the appointment of Jim Greenwell as Executive Advisor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326786868/en/
Jim Greenwell (Photo: Business Wire)
Greenwell joins the company with deep experience in the digital identity and mobility space, most recently serving as an executive adviser to Thomson Reuters and AuthenticID, as well as serving on the advisory boards of Prove and Gravy Analytics. Jim is the former CEO of Danal, Inc., having led the company’s growth and innovation within the mobile identity and authentication space for over a decade through its sale to Boku, Inc. (LON: BOKU) in 2019. During his tenure, Jim created successful global partnerships and enduring customer relationships in a broad range of industries, including financial services, government, e-commerce, and wireless. One World Identity recognized Jim as one of the top four CEOs in Identity and Authentication in 2018 and one of the “Top 100 Influencers in Identity” in 2019.
Prior to Danal, Jim was CEO and President at ACE*COMM Corporation focusing on Telecom OSS/BSS software. Prior to ACE*COMM, Jim was the COO/SVP of the Americas and AsiaPac for LCC International where he grew the mobile network design business. Jim began his career as a military intelligence officer in the U.S. Army where he served in Northern Iraq and Turkey as part of the Kurdish relief effort following Desert Storm.
In his role as Executive Advisor, Greenwell will collaborate closely with Trustfull's leadership team to further enhance the platform's capabilities and drive its expansion into new markets.
Commenting on the appointment, Trustfull CEO Marko Maras said, "We are thrilled to welcome Jim to Trustfull as our Executive Advisor. His deep understanding of the industry and proven track record of driving growth and innovation will be invaluable as we continue to empower businesses with advanced fraud prevention solutions."
Jim Greenwell also expressed his enthusiasm about joining Trustfull, stating, "I am honored to join Trustfull as Executive Advisor. The company's commitment to leveraging cutting-edge technology to combat fraud is truly impressive, and I look forward to working closely with the team to further strengthen Trustfull's position as a leader in the industry."
Greenwell's appointment comes at a pivotal time for Trustfull as it continues to innovate and expand its suite of fraud prevention solutions, helping businesses mitigate risks and protect their assets in an increasingly digital landscape.
About Trustfull
Trustfull is a cloud-based digital risk intelligence platform. Utilizing silent checks on multiple signals including phone number, email address, IP address, device, and browser, Trustfull helps companies across different industries assess risks an provide a safer online experience. Main use cases include: KYC, AML, Account Takeover, Promo Abuse and Transaction Monitoring.
For more information: http://www.trustfull.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326786868/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom